2020;39(19):e105802
This makes CagriSema different from tirzepatide and retatrutide
This peptide is derived from a naturally occurring protein found in human gastric juice
Potential side effects may include injection-site redness, swelling, bruising, itching, tenderness, small lumps, headache, fatigue, nausea, appetite changes, abdominal discomfort, stool changes, dizziness, altered sleep, mood changes, or feeling off. Allergic or immune reactions are also possible, and the FDA has specifically raised concerns about immunogenicity and peptide-related impurities in compounded BPC-157
Inclusion of these substances on the 503A Bulks List will likely take time to implement, should the committee decide to move forward with them
10.1007/s00403-010-1045-4